Obama Alzheimer's 'roadmap' targets Genentech drug for 'landmark' prevention study
This article was originally published in Scrip
Researchers in the Alzheimer's disease community should quickly familiarize themselves with an experimental drug from US Roche unit Genentech called crenezumab, National Institutes of Health (NIH) Director Dr Francis Collins declared on 15 May, in revealing a new public-private study collaboration between the US government, the South San Francisco-based company and the Arizona nonprofit Banner Alzheimer's Institute.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.